Table 3.
Independent predictors for the primary outcome
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age | 1.043 | 1.008–1.079 | 0.016 | |||
| IHD | 4.333 | 1.811–10.366 | 0.001 | 2.743 | 1.119–6.728 | 0.027 |
| Beta‐blocker | 0.164 | 0.063–0.427 | 0.000 | 0.170 | 0.054–0.540 | 0.003 |
| Spironolactone | 0.385 | 0.162–0.914 | 0.031 | 0.377 | 0.147–0.963 | 0.042 |
| Delayed use of Sac/Val a | 2.871 | 1.158–7.113 | 0.023 | 2.737 | 1.076–6.962 | 0.035 |
CI, confidence interval; HR, hazard ratio; IHD, ischaemic heart disease; Sac/Val, sacubitril/valsartan.
a
Use of Sac/Val 3 months after diagnosis of heart failure with reduced ejection fraction, as in the later use group.